Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ITC to hear Roche claim against Organon Teknika alleging quantitative HIV test patent infringement.

This article was originally published in The Gray Sheet

Executive Summary

ITC TO HEAR ROCHE'S COMPLAINT AGAINST ORGANON TEKNIKA for allegedly infringing technology in its quantitative HIV RNA load polymerase chain reaction test. In a Federal Register notice to be published the week of July 29, the International Trade Commission says it decided July 22 to hear Nutley, New Jersey-based Hoffmann-La Roche's complaint against Organon Teknika B.V. of the Netherlands and its Durham, North Carolina subsidiary, Organon Teknika Corporation. Roche alleges that Organon's NASBA HIV-1 RNA QT kit infringes Roche's U.S. patent on technology which allows precise quantification of nucleic acids. Roche is requesting the ITC to bar import of Organon's kits into the U.S. Organon is importing the tests for research use.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel